OSS, Netherlands — On 9 September 2019 Glycostem and an undisclosed Korean partner confirmed the signing of two agreements.
The Korean partner has secured the Korea and Japan commercialisation rights for oNKord® for the indications AML and MM. At the same time the parties entered into a global development agreement for a CAR-NK product with an undisclosed target.
Glycostem’s CEO, Troels Jordansen, said “We are delighted to have attracted the attention of a large Asia-focused pharmaceutical company with oNKord® and the development of a CAR-NK product. These developments further validate the growing expectation for off-the-shelf NK-cells, a product unique to Glycostem.”
Jordansen added, “We have funding in place for phase I and IIa and are looking forward to sharing this data with our partners while in the process of obtaining product approvals globally. We are now turning our attention to identifying commercialisation partners for oNKord® in the USA and Europe.”